Coatue Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$41.5M Hold
3,836,986
– – 0.08% 48
2026
Q2
$36.1M Hold
3,836,986
– – 0.07% 43
2026
Q1
$31.2M Buy
+3,836,986
New +$34.8M 0.11% 42
2025
Q4
– Sell
-3,836,986
Closed -$33.3M – 67
2025
Q3
$33.3M Hold
3,836,986
– – 0.08% 54
2025
Q2
$24.2M Hold
3,836,986
– – 0.07% 53
2025
Q1
$24.6M Buy
+3,836,986
New +$31.7M 0.11% 45
2024
Q4
– Sell
-2,224,319
Closed -$28.1M – 84
2024
Q3
$28.1M Sell
2,224,319
-400,596
-15% -$5.17M 0.1% 58
2024
Q2
$33.2M Buy
2,624,915
+1,105,321
+73% +$11.1M 0.13% 46
2024
Q1
$7.26M Hold
1,519,594
– – 0.03% 80
2023
Q4
$7.29M Buy
+1,519,594
New +$9.3M 0.03% 81
2023
Q3
– Sell
-1,039,123
Closed -$7.72M – 96
2023
Q2
$7.72M Sell
1,039,123
-726,936
-41% -$5.72M 0.04% 74
2023
Q1
$12.2M Buy
1,766,059
+1,462,000
+481% +$13.5M 0.08% 57
2022
Q4
$3.13M Sell
304,059
-243,496
-44% -$4.3M 0.04% 66
2022
Q3
$10M Sell
547,555
-694,161
-56% -$30.1M 0.12% 66
2022
Q2
$63.9M Buy
1,241,716
+358,270
+41% +$18.6M 0.77% 31
2022
Q1
$65.1M Buy
+883,446
New +$78.8M 0.48% 33

Other funds holding NVAX

Coatue Management's NVAX Position: Q3 2026 in Review

Coatue Management held its Novavax (NVAX) position steady in Q3 2026 at 3,836,986 shares worth $41.5M. The position accounts for 0.08% of the portfolio, ranked #48.

Coatue Management first reported a position in NVAX in Q1 2022 and has held it in 16 quarters since. The position peaked at $65.1M in Q1 2022. 261 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

  • Coatue Management held 3,836,986 shares of Novavax worth $41.5M as of Q3 2026.
  • Coatue Management left its Novavax share count unchanged in Q3 2026.
  • Novavax made up 0.08% of Coatue Management's portfolio in Q3 2026, its #48 holding.
  • Coatue Management first reported a position in Novavax in Q1 2022 and has held it in 16 quarters since.
  • Coatue Management's Novavax position peaked at $65.1M in Q1 2022.
  • 261 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on Coatue Management's 13F filing for Q3 2026, filed 16 Nov 2026.